Targeted  ||| S:0 E:9 ||| JJ
therapy  ||| S:9 E:17 ||| NN
for  ||| S:17 E:21 ||| IN
hereditary  ||| S:21 E:32 ||| JJ
cancer  ||| S:32 E:39 ||| NN
syndromes ||| S:39 E:48 ||| NNS
:  ||| S:48 E:50 ||| :
neurofibromatosis  ||| S:50 E:68 ||| JJ
type  ||| S:68 E:73 ||| NN
1 ||| S:73 E:74 ||| CD
,  ||| S:74 E:76 ||| ,
neurofibromatosis  ||| S:76 E:94 ||| JJ
type  ||| S:94 E:99 ||| NN
2 ||| S:99 E:100 ||| CD
,  ||| S:100 E:102 ||| ,
and  ||| S:102 E:106 ||| CC
Gorlin  ||| S:106 E:113 ||| NNP
syndrome  ||| S:113 E:122 ||| NN
Hereditary  ||| S:122 E:133 ||| NNP
cancer  ||| S:133 E:140 ||| NN
syndromes  ||| S:140 E:150 ||| NNS
are  ||| S:150 E:154 ||| VBP
well  ||| S:154 E:159 ||| RB
known  ||| S:159 E:165 ||| VBN
in  ||| S:165 E:168 ||| IN
the  ||| S:168 E:172 ||| DT
oncology  ||| S:172 E:181 ||| JJ
community ||| S:181 E:190 ||| NN
,  ||| S:190 E:192 ||| ,
typically  ||| S:192 E:202 ||| RB
affecting  ||| S:202 E:212 ||| VBG
children ||| S:212 E:220 ||| NNS
,  ||| S:220 E:222 ||| ,
adolescents ||| S:222 E:233 ||| NNS
,  ||| S:233 E:235 ||| ,
and  ||| S:235 E:239 ||| CC
young  ||| S:239 E:245 ||| JJ
adults  ||| S:245 E:252 ||| NNS
and  ||| S:252 E:256 ||| CC
thereby  ||| S:256 E:264 ||| RB
resulting  ||| S:264 E:274 ||| VBG
in  ||| S:274 E:277 ||| IN
great  ||| S:277 E:283 ||| JJ
cumulative  ||| S:283 E:294 ||| JJ
morbidity  ||| S:294 E:304 ||| NN
and  ||| S:304 E:308 ||| CC
mortality ||| S:308 E:317 ||| NN
.  ||| S:317 E:319 ||| .
These  ||| S:319 E:325 ||| DT
syndromes  ||| S:325 E:335 ||| NN
often  ||| S:335 E:341 ||| RB
lag  ||| S:341 E:345 ||| VB
behind  ||| S:345 E:352 ||| IN
their  ||| S:352 E:358 ||| PRP$
de  ||| S:358 E:361 ||| FW
novo  ||| S:361 E:366 ||| FW
counterparts  ||| S:366 E:379 ||| NNS
in  ||| S:379 E:382 ||| IN
the  ||| S:382 E:386 ||| DT
development  ||| S:386 E:398 ||| NN
of  ||| S:398 E:401 ||| IN
approved  ||| S:401 E:410 ||| JJ
novel  ||| S:410 E:416 ||| NN
treatment  ||| S:416 E:426 ||| NN
options  ||| S:426 E:434 ||| NNS
due  ||| S:434 E:438 ||| JJ
to  ||| S:438 E:441 ||| TO
their  ||| S:441 E:447 ||| PRP$
rarity  ||| S:447 E:454 ||| NN
in  ||| S:454 E:457 ||| IN
the  ||| S:457 E:461 ||| DT
general  ||| S:461 E:469 ||| JJ
population ||| S:469 E:479 ||| NN
.  ||| S:479 E:481 ||| .
Recent  ||| S:481 E:488 ||| JJ
work  ||| S:488 E:493 ||| NN
has  ||| S:493 E:497 ||| VBZ
allowed  ||| S:497 E:505 ||| VBN
the  ||| S:505 E:509 ||| DT
identification  ||| S:509 E:524 ||| NN
of  ||| S:524 E:527 ||| IN
molecular  ||| S:527 E:537 ||| JJ
aberrations  ||| S:537 E:549 ||| NN
and  ||| S:549 E:553 ||| CC
associated  ||| S:553 E:564 ||| VBN
targeted  ||| S:564 E:573 ||| VBN
therapies  ||| S:573 E:583 ||| NNS
that  ||| S:583 E:588 ||| WDT
may  ||| S:588 E:592 ||| MD
effectively  ||| S:592 E:604 ||| RB
treat  ||| S:604 E:610 ||| VB
these  ||| S:610 E:616 ||| DT
conditions ||| S:616 E:626 ||| NNS
.  ||| S:626 E:628 ||| .
In  ||| S:628 E:631 ||| IN
this  ||| S:631 E:636 ||| DT
review ||| S:636 E:642 ||| NN
,  ||| S:642 E:644 ||| ,
we  ||| S:644 E:647 ||| PRP
seek  ||| S:647 E:652 ||| VBP
to  ||| S:652 E:655 ||| TO
characterize  ||| S:655 E:668 ||| VB
some  ||| S:668 E:673 ||| DT
of  ||| S:673 E:676 ||| IN
the  ||| S:676 E:680 ||| DT
involved  ||| S:680 E:689 ||| JJ
aberrations  ||| S:689 E:701 ||| NN
and  ||| S:701 E:705 ||| CC
associated  ||| S:705 E:716 ||| VBN
targeted  ||| S:716 E:725 ||| VBN
therapies  ||| S:725 E:735 ||| NNS
for  ||| S:735 E:739 ||| IN
several  ||| S:739 E:747 ||| JJ
germline  ||| S:747 E:756 ||| JJ
malignancies ||| S:756 E:768 ||| NN
,  ||| S:768 E:770 ||| ,
including  ||| S:770 E:780 ||| VBG
neurofibromatosis  ||| S:780 E:798 ||| JJ
types  ||| S:798 E:804 ||| NNS
1  ||| S:804 E:806 ||| CD
and  ||| S:806 E:810 ||| CC
2 ||| S:810 E:811 ||| CD
,  ||| S:811 E:813 ||| ,
and  ||| S:813 E:817 ||| CC
Gorlin  ||| S:817 E:824 ||| NNP
syndrome ||| S:824 E:832 ||| NN
.  ||| S:832 E:834 ||| .
Though  ||| S:834 E:841 ||| IN
patients  ||| S:841 E:850 ||| NNS
with  ||| S:850 E:855 ||| IN
hereditary  ||| S:855 E:866 ||| JJ
cancer  ||| S:866 E:873 ||| NN
syndromes  ||| S:873 E:883 ||| NNS
may  ||| S:883 E:887 ||| MD
be  ||| S:887 E:890 ||| VB
too  ||| S:890 E:894 ||| RB
rare  ||| S:894 E:899 ||| JJ
to  ||| S:899 E:902 ||| TO
effectively  ||| S:902 E:914 ||| RB
include  ||| S:914 E:922 ||| VB
in  ||| S:922 E:925 ||| IN
large  ||| S:925 E:931 ||| JJ
clinical  ||| S:931 E:940 ||| JJ
trials ||| S:940 E:946 ||| NNS
,  ||| S:946 E:948 ||| ,
by  ||| S:948 E:951 ||| IN
understanding  ||| S:951 E:965 ||| VBG
the  ||| S:965 E:969 ||| DT
pathophysiology  ||| S:969 E:985 ||| NN
of  ||| S:985 E:988 ||| IN
these  ||| S:988 E:994 ||| DT
diseases ||| S:994 E:1002 ||| NNS
,  ||| S:1002 E:1004 ||| ,
clinicians  ||| S:1004 E:1015 ||| NNS
can  ||| S:1015 E:1019 ||| MD
attain  ||| S:1019 E:1026 ||| VB
insights  ||| S:1026 E:1035 ||| NNS
into  ||| S:1035 E:1040 ||| IN
the  ||| S:1040 E:1044 ||| DT
use  ||| S:1044 E:1048 ||| NN
of  ||| S:1048 E:1051 ||| IN
targeted  ||| S:1051 E:1060 ||| JJ
therapies  ||| S:1060 E:1070 ||| NNS
in  ||| S:1070 E:1073 ||| IN
their  ||| S:1073 E:1079 ||| PRP$
own  ||| S:1079 E:1083 ||| JJ
practice  ||| S:1083 E:1092 ||| NN
when  ||| S:1092 E:1097 ||| WRB
treating  ||| S:1097 E:1106 ||| VBG
affected  ||| S:1106 E:1115 ||| JJ
individuals ||| S:1115 E:1126 ||| NNS
.  ||| S:1126 E:1128 ||| .
